What if Ocre doesn't get approval?

Quote
Seriously, how stupid is this thread?
Does anyone on here know what breakthrough therapy designation is or implies?
Chances this drug isn't getting approval are slim and none, and slim already walked out the door. Get a grip, people
 
























Even if scenario is: Ocre approved in Dec. 2016 with launch Jan. 2017 then possible generic bio similar by late 2018, I'm ok with getting high end salary & bennies for 6 months of training & relationship building with customers followed by at least 3-4 years of active promotion of the product. This train will travel well and doesn't stop at the station for a good long while. Four years on top in this industry?- Take it. It will be hard to match. Signed, a veteran lacking the bs gene.
 






anonymous said:
Even if scenario is: Ocre approved in Dec. 2016 with launch Jan. 2017 then possible generic bio similar by late 2018, I'm ok with getting high end salary & bennies for 6 months of training & relationship building with customers followed by at least 3-4 years of active promotion of the product. This train will travel well and doesn't stop at the station for a good long while. Four years on top in this industry?- Take it. It will be hard to match. Signed, a veteran lacking the bs gene.
Click to expand...

Thats the spirit, Pal. You must have wowed them with your share stories filled with strategic agility and teamwork and collab. Your awesome. Better get busy with your development plan.
 






Laughable thread! Years of MS experience here and I know a lot more than the rest of these competitors posting here...that's why I came here. Ocre will mop everyone up and the competitors know it. They are planting seeds that simply won't sprout.

Say goodbye..Avonex, Betaseron, Rebif, Copaxone, Tysabri, Lemtrada.

The future will be a trial of Aubagio followed by Ocre...the rest of the therapies are so yesterday..CRAB's will be dead for sure. Gilenya may survive but low market shares.

So competitors..kiss our arse because yours is about to be kicked.
 






Didn't the ongoing trial just have 3 PML cases out of Cleveland Clinic? Oh wait your head is in sand so you don't know correct? Prepare to be shocked once it's made public. Newbie!
 












Rituxian's patents in Europe expired in 2013. It generated $7.6 billion in sales in 2013 - twenty percent of Roche's sales, and big pharma companies including Pfizer (NYSE:PFE), Novartis (NYSE:NVS), Merck (NYSE:MRK), Teva (NYSE:TEVA) and Boehringer Ingelheim are just a few of the companies that initiated programs to launch a biosimilar Rituxan. (!). Rituximab generics are expected to enter the US market in early 2017.


So my question is why use Ocre when a generic is available?
 


















anonymous said:
Rituxian's patents in Europe expired in 2013. It generated $7.6 billion in sales in 2013 - twenty percent of Roche's sales, and big pharma companies including Pfizer (NYSE:PFE), Novartis (NYSE:NVS), Merck (NYSE:MRK), Teva (NYSE:TEVA) and Boehringer Ingelheim are just a few of the companies that initiated programs to launch a biosimilar Rituxan. (!). Rituximab generics are expected to enter the US market in early 2017.


So my question is why use Ocre when a generic is available?
Click to expand...

Exactly! Why pay a higher premium for Ocre when cheaper Rituxin has worked just fine. If I were a managed care company, I wouldn't pay to transfer a patient from Rituxin to Ocre. Happy warehousing.
 






























anonymous said:
Laughable thread! Years of MS experience here and I know a lot more than the rest of these competitors posting here...that's why I came here. Ocre will mop everyone up and the competitors know it. They are planting seeds that simply won't sprout.

Say goodbye..Avonex, Betaseron, Rebif, Copaxone, Tysabri, Lemtrada.

The future will be a trial of Aubagio followed by Ocre...the rest of the therapies are so yesterday..CRAB's will be dead for sure. Gilenya may survive but low market shares.

So competitors..kiss our arse because yours is about to be kicked.
Click to expand...

PG U ARE TOO FUNNY
 






anonymous said:
Laughable thread! Years of MS experience here and I know a lot more than the rest of these competitors posting here...that's why I came here. Ocre will mop everyone up and the competitors know it. They are planting seeds that simply won't sprout.

Say goodbye..Avonex, Betaseron, Rebif, Copaxone, Tysabri, Lemtrada.

The future will be a trial of Aubagio followed by Ocre...the rest of the therapies are so yesterday..CRAB's will be dead for sure. Gilenya may survive but low market shares.

So competitors..kiss our arse because yours is about to be kicked.
Click to expand...

PG U ARE TOO FUNNY
 






Top Bottom
Back
Quote